| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.5 | 8.8 |
| Profit before tax | -29.5 | -8.7 |
| Net income | -29.5 | -10.9 |
| EPS (diluted, $ a share) | $-1.05 | $-2.29 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -71.8% |
|---|
10-Q filed with the SEC, NASDAQ: APMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Apnimed, Inc.: key numbers
- Share price
- $16.28Close, Nov 16
- Market cap
- $678M
- Shares outstanding
- 41.63MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Apnimed, Inc.
All →Apnimed Financial Results
Apnimed reported third quarter 2026 financial results, highlighting a cash position of $351.8 million following its upsized IPO in August. The company's NDA for AD109 (Oxnimbi) for the treatment of obstructive sleep apnea remains under FDA review with a PDUFA goal date of February 28, 2027.
“We are in a transformational period at Apnimed. With our NDA for AD109 (proposed proprietary name Oxnimbi) under FDA review and a PDUFA goal date of February 28, 2027, we are advancing our launch readiness while continuing to strengthen the clinical story.”
Kevin Lind, Chief Executive Officer of Apnimed
Apnimed Other 8-K Filing
Apnimed, Inc. announced that its previously issued financial statements for the three and six months ended June 30, 2026, should no longer be relied upon due to an accounting error. The error involves the misclassification of an $85.4 million gain from the sale of its interest in Shionogi-Apnimed Sleep Science, LLC as continuing operations rather than discontinued operations. The company intends to file a restatement on Form 10-Q/A to correct the classification, which does not impact total net income, cash, or total assets.
- Counterparty
- Shionogi & Co., Ltd.